Markets: Three stocks analysts are chasing as the AI rally cools
The article says investors are rotating from highly valued AI infrastructure toward healthcare, citing a Bank of America survey and recent sector performance. It highlights three healthcare stocks: Aurinia Pharmaceuticals (AUPH) with Q1 revenue $77.7M and EPS $0.25; Fortrea (FTRE) raising full-year sales and adjusted EBITDA; and Aveanna (AVAH) after a $175.5M acquisition, guiding FY revenue $2.63B-$2.65B.
How this was made
The 30-second read
Why it matters
It spotlights three healthcare stocks and cites specific growth metrics, forecast changes, and one acquisition, implying relative outperformance potential during a defensive rotation.
Market read
Useful for identifying healthcare defensives that the market may rotate into, but it does not introduce a single clearly new, time-stamped catalyst for each name.
What to watch
For small/mid-cap healthcare names, execution risk (trial/regulatory timelines for AUPH, contract conversion and pricing for FTRE, reimbursement and integration for AVAH) could offset the optimistic narrative.
Background
The piece argues that as AI infrastructure valuations cool, capital is moving toward healthcare companies with earnings growth less tied to the economic cycle.
Ticker impact
Aurinia is highlighted for strong Q1 growth and a management shakeup, with EPS growth expectations up to 200% vs estimates.
Near-term trading bias likely positive, but catalyst is more narrative than a fresh filing or guidance print.
The text includes specific Q1 financial growth and leadership changes, but it does not present a newly released guidance update or regulatory/product event dated to today.
Fortrea is described as raising full-year sales and adjusted EBITDA forecasts after strong first-half performance and contract growth.
Moderately bullish bias, with upside sensitivity to continued contract/order-to-bill strength.
The article provides concrete operational metrics (order-to-bill, contract growth) and forecast raises, but it is not clear these are newly disclosed today versus “released this week” context.
Aveanna is highlighted after completing a $175.5 million acquisition of Family First Homecare and raising 2026 revenue and adjusted EBITDA guidance.
Likely supportive for momentum trades, especially for investors targeting guidance-up cycles in home health.
The article states deal size, timing (early June), and explicit updated revenue and adjusted EBITDA ranges, which are actionable for valuation and near-term positioning.
Market effects
Reinforces a rotation narrative toward healthcare defensives (pharma, services, clinical research) as investors seek less cyclical earnings.
No specific regional policy or macro shock tied to a geography beyond general US market references.
Mentions global investors increasing healthcare allocation, but without country-specific catalysts.
Counterpoint
The article is largely a “three stocks to chase” framing; without fresh, dated disclosures, the trade may be more sentiment-driven than fundamentals-driven.
Key entities
- companyAurinia Pharmaceuticals
Lupus nephritis drug Lupkynis seller; Q1 sales, profit, and EPS growth plus CEO/CFO changes are cited.
- companyFortrea Holdings
Contract clinical trial provider; contract growth, order-to-bill, and raised full-year sales and adjusted EBITDA forecasts are cited.
- companyAveanna Healthcare Holdings
Home health and nursing services provider; $175.5 million Family First Homecare acquisition and raised guidance are cited.
